SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin receives EIR from US FDA for Goa facility

08 Jul 2016 Evaluate

Pharma Major Lupin has received notification that the inspection carried out by the US FDA in July 2015 at its Goa facility is now closed and the agency has issued an Establishment Inspection Reports (EIR). However, the responses from the March 2016 US FDA inspection and updates thereafter are still under review by the agency.

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin Share Price

2257.40 -120.50 (-5.07%)
11-May-2026 10:18 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1866.90
Dr. Reddys Lab 1277.10
Cipla 1339.45
Zydus Lifesciences 935.15
Lupin 2257.40
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×